Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that group behavior therapy for trichotillomania led to greater short-term symptom improvement compared to supportive therapy, but did not achieve clinically significant changes or prevent relapse over six months.

This article reviews IFAP syndrome, an X-linked genetic disorder characterized by ichthyosis follicularis, alopecia, and photophobia, and reports no new clinical findings.

This study found that a topical cream containing PTH (7–34) significantly stimulated hair growth in hairless mice.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This article discusses temporal triangular alopecia, emphasizing the need for increased awareness to prevent misdiagnosis and ineffective treatment, but reports no new clinical results.

This study identified an unexpected critical role for the FATP4 protein in skin and hair development in mice, linking it to a potential candidate gene for restrictive dermopathy in humans.

This study concluded that platelet-rich plasma therapy was as effective as intralesional triamcinolone acetonide in treating localized alopecia areata on the scalp.

In this case report, an 11-year-old girl with hypothyroidism was found to have Hashimoto thyroiditis after presenting with hair loss, short stature, and pubertal disturbances; the study emphasizes the importance of early diagnosis and personalized thyroid hormone therapy for better outcomes.

In this study, a 37-year-old Moroccan man experienced hair loss after two months of quetiapine treatment for major depressive disorder, which resolved after discontinuation, highlighting the need for awareness of this potential rare side effect.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

In this study, plerixafor was found to enhance melanogenesis and promote repigmentation by engaging a β-arrestin–β-catenin–MITF signaling axis in melanocytes, and showed effectiveness in restoring depigmentation in a murine model without causing systemic toxicity.

In this cross-sectional study conducted at Farhat Hached Hospital in Tunisia, more than half of the 60 alopecia areata patients surveyed experienced depression, particularly younger individuals and those with severe or specific forms of the condition, underscoring the need for psychological support.

This study found that Pmab treatment may alter hair follicle growth cycles, leading to trichomegaly and hypertrichosis, but these effects do not correlate with other skin toxicities.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

This case report describes a young girl with trichothiodystrophy and suggests the need for early diagnosis and multidisciplinary interventions for her educational challenges.

This study found that oral etretinate improved skin conditions like erythrodermic and pustular psoriasis, although less so for psoriasis vulgaris and lichen planus, with notable side effects including cheilitis and mucous membrane dryness.

This report details the case of an 11-year-old girl with APECED syndrome carrying a unique homozygous mutation in the AIRE gene, the first of its kind documented.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

In this report, a young Caucasian woman developed a hairy tongue as an unusual side effect during baricitinib therapy for severe alopecia areata, which was managed by daily toothbrush debridement.

This study describes a 62-year-old male with trichodaganomania, an urge to bite his mustache hair, who was treated with counseling and placebo medication, highlighting the need for a comprehensive treatment approach including potential psychological and psychiatric interventions if symptoms recur.

In this study, researchers found that alopecia significantly impacts depression and quality of life, especially for those with hereditary baldness in the Eastern Province of Saudi Arabia, and emphasized the need for psychological support to improve mental health.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

This study reviewed isotretinoin's effectiveness in treating moderate to severe acne and discussed the need to balance its robust treatment benefits with careful monitoring due to significant physiological and psychological side effects.

This study suggests that hydroxychloroquine may benefit some children with alopecia areata, as five out of nine patients showed improvement, although side effects like gastrointestinal intolerance and headache were noted.

This article reviews the cutaneous reactions associated with targeted cancer therapies and highlights the importance of dermatologists recognizing these reactions to provide effective care but reports no clinical results.

This article discusses the limitations of hair transplants in treating androgenetic alopecia and stresses that this progressive condition lacks a perfect treatment solution.

This study reported six pediatric cases of temporal triangular alopecia and highlighted the use of trichoscopy to distinguish it by detecting a distinctive carpet of vellus hair, helping to differentiate TTA from other hair loss conditions.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study conducted in the Kingdom of Saudi Arabia reported that severe alopecia areata presents significant treatment challenges due to limited therapies, leading to substantial impacts on patients' quality of life, mental health, and economic burdens.